• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Chronic Disease

Brentuximab-based chemotherapy improves survival and reduces toxicity in patients with advanced Hodgkin lymphoma

byNeel MistryandTeddy Guo
August 28, 2024
in Chronic Disease, Hematology, Oncology
Reading Time: 2 mins read
Share on FacebookShare on TwitterShare on LinkedIn

1. BrECADD resulted in significantly lower treatment-related morbidity than eBEACOPP.

2. Progression-free survival at 48 months was significantly greater in the BrECADD group compared to the eBEACOPP group.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Intensified systemic chemotherapy provides high cure rates, albeit with severe and long-lasting toxicities, in patients with advanced-stage classical Hodgkin lymphoma. The BrECADD regimen (brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone) aims to reduce these toxicities while maintaining treatment effectiveness compared to current treatment regimens. This randomized controlled trial aimed to compare the tolerability and efficacy of BrECADD with the standard eBEACOPP regimen (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) in patients with newly diagnosed advanced-stage classical Hodgkin lymphoma. The primary outcome of this study was tolerability of treatment, defined as treatment-related morbidity, while the key secondary outcome was progression-free survival. According to study results, the BrECADD demonstrated significantly improved morbidity and progression-free survival compared to the eBEACOPP group. Although this study was well done, it was limited by the open-label design, which could introduce bias in treatment assessment.

Click to read the study in The Lancet

Relevant Reading: Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma

RELATED REPORTS

101-PGC-005 improved hospitalized patients with COVID-19 faster than systemic dexamethasone in topline phase 2/3 results

Male sex is associated with higher mortality among patients with hepatocellular carcinoma

In-depth [randomized controlled trial]: Between Jul 22, 2016, and Aug 27, 2020, 1500 patients were assessed for eligibility across 9 countries. Included were patients ≤ 60 years with new-onset, advanced-stage Hodgkin lymphoma (Ann Arbor stage III/IV or stage II with constitutional symptoms). Altogether, 1482 patients (740 in eBEACOPP and 742 in BrECADD) were included in the final analysis. Majority of patients were White (91%) and male (56%). The primary outcome of treatment-related morbidity showed significantly lower rates in the BrECADD group compared to the eBEACOPP group (42% vs. 59%, relative risk [RR] 0.72, 95% confidence interval [CI] 0.65-0.80, p<0.0001). Moreover, the secondary outcome of progression-free survival also favored BrECADD (hazard ratio [HR] 0.66, p=0.035), with higher 4-year progression-free survival rates (94.3% for BrECADD and 90.9% for eBEACOPP). Overall, findings from this study suggest that the BrECADD regimen is more tolerable and more effective than eBEACOPP for first-line treatment of advanced-stage classical Hodgkin lymphoma.

Image: PD

©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: advanced-stage classical Hodgkin lymphomaBrECADDcyclophosphamidedacarbazinedexamethasonedoxorubicineBEACOPPetoposidehematologyHodgkin Lymphomalymphomaoncologyprednisoneprocarbazinevincristine
Previous Post

#VisualAbstract: Adjuvant Pembrolizumab Shows Similar Outcomes to Placebo in Resected Stage III Melanoma

Next Post

Sex related differences associated with atrial fibrillation post cardiac surgery

RelatedReports

A balance scale weighing an antiviral medication against a hospital entrance and a patient, symbolizing the outcomes of COVID-19 treatment.
2MM Trial Briefs

101-PGC-005 improved hospitalized patients with COVID-19 faster than systemic dexamethasone in topline phase 2/3 results

November 10, 2026
A liver illustration with spilled sugar cubes and two drink cups, highlighting the link between sugary drinks and liver health.
Chronic Disease

Male sex is associated with higher mortality among patients with hepatocellular carcinoma

October 7, 2026
The image features a woman examining samples under a microscope, representations of cancer cells, a knee joint, and a liver with a pill at the center, suggesting a focus on oncology and pharmaceutical therapy.
Oncology

Daraxonrasib extends survival in metastatic pancreatic cancer

September 17, 2026
Quick Take: Diagnostic Yield of One-Time Colonoscopy vs One-Time Flexible Sigmoidoscopy vs Multiple Rounds of Mailed Fecal Immunohistochemical Tests in Colorectal Cancer Screening
Chronic Disease

Molecularly guided therapy may improve outcomes in patients with unfavourable cancer of unknown primary compared with standard chemotherapy

September 7, 2026
Next Post

Sex related differences associated with atrial fibrillation post cardiac surgery

#VisualAbstract Routine Administration of Protamine Improves Outcomes After Transfemoral Transcatheter Aortic Valve Implantations

#VisualAbstract Routine Administration of Protamine Improves Outcomes After Transfemoral Transcatheter Aortic Valve Implantations

Pimecrolimus effective first-line treatment for atopic dermatitis

Delgocitinib cream is effective and safe for the treatment of chronic hand eczema

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Large genetic association study identifies additional Alzheimer disease risk loci and candidate pathways
  • Pelacarsen lowers lipoprotein(a) but does not reduce major cardiovascular events in patients with established cardiovascular disease
  • Durvalumab plus enfortumab vedotin was approved for perioperative treatment of muscle-invasive bladder cancer
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.